CompletedPHASE2, PHASE3NCT00454480
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Studying Acute basophilic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The University of New South Wales
- Principal Investigator
- Alan K. Burnett, MD, FRCPUniversity Hospital of Wales
- Intervention
- alemtuzumab(biological)
- Enrollment
- 2000 enrolled
- Eligibility
- All sexes
- Timeline
- 2006
Study locations (30)
- Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom
- Royal United Hospital, Bath, England, United Kingdom
- Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom
- Birmingham Heartlands Hospital, Birmingham, England, United Kingdom
- Blackpool Victoria Hospital, Blackpool, England, United Kingdom
- Royal Bournemouth Hospital, Bournemouth, England, United Kingdom
- Bradford Royal Infirmary, Bradford, England, United Kingdom
- Sussex Cancer Centre at Royal Sussex County Hospital, Brighton, England, United Kingdom
- Queen's Hospital, Burton-on-Trent, England, United Kingdom
- West Suffolk Hospital, Bury St Edmunds, England, United Kingdom
- Addenbrooke's Hospital, Cambridge, England, United Kingdom
- Kent and Canterbury Hospital, Canterbury, England, United Kingdom
- St. Helier Hospital, Carshalton, England, United Kingdom
- Gloucestershire Oncology Centre at Cheltenham General Hospital, Cheltenham, England, United Kingdom
- Countess of Chester Hospital, Chester, England, United Kingdom
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00454480 on ClinicalTrials.govOther trials for Acute basophilic leukemia
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT01627041Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid LeukemiaNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNCT00898456Multidrug Resistance Genes in Patients With Acute Myeloid LeukemiaAlliance for Clinical Trials in Oncology